Menu

Methodology FAQ About Run a backtest

Would buying the dips on MRNA have beaten holding it?

Large-cap biotech. A volatile large-cap with a strong hypothetical year. Hypothetical last-12-month dip-grid on listed US hourly bars. $100,000 capital · $15,000 lots · −2% / +12.5%.

• Window 2025-10-01 → 2026-09-30
• Total return (cash + open lots) +166.24%
• Realized P&L (sold lots only) +166.39%
• Buy-and-hold, same capital +636.63%
• Max drawdown -14.95% · 2 lots still open

Open the MRNA sample book · Run your own ticker for $1

Not investment advice. Past performance does not guarantee future results.